Xeris Pharmaceuticals Inc. (XERS) has a PDUFA on September 10, 2019, for a device-drug combo that delivers room-temperature, ready-to-use glucagon to hypoglycemia patients. Last year, around September, a month before its NDA was accepted by the FDA, the stock traded at its all-time high of around $28. Then it fell. It had a brief rally around October, when the NDA acceptance news came out; then it started falling. The free fall continued all the way till February, when the company announced a secondary. Then it fell some more. Finally, the stock found bottom